Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 5/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | FBP1 | P09467 | 13/20 | 0.41 |
| ▸ | PPARG | P37231 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6924904 | 0.84 | DHODH (0.39) | PPARACYP1A2CYP3A4PPARG | |
| SCHEMBL6502505 | 0.75 | AR (0.43) | CYP1A2TSHR | |
| SCHEMBL6502479 | 0.74 | PDE3B (0.50) | TSHR | |
| SCHEMBL6487097 | 0.73 | CA12 (0.46) | PPARG | |
| SCHEMBL3962137 | 0.73 | DHODH (0.43) | — | |
| SCHEMBL6927743 | 0.72 | PPARA (0.39) | PPARACYP1A2TSHRPPARG | |
| SCHEMBL6926116 | 0.71 | SMN1; SMN2 (0.55) | PPARAPPARG | |
| SCHEMBL3963475 | 0.70 | ALDH1A1 (0.40) | — | |
| SCHEMBL6487758 | 0.70 | PPARA (0.56) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL6923484 | 0.69 | MCL1 (0.47) | PPARACYP1A2TSHRPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108686-A2 | BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | PPARA 665/4885ABCB11 140/4885CYP1A2 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.